Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11421548 | 0.86 | ACHE (0.52) | ALDH1A1CYP3A4TDP1TP53SMN1; SMN2 | |
| SCHEMBL15340900 | 0.81 | TEAD4 (0.48) | ALDH1A1CYP3A4TDP1TP53THRB | |
| SCHEMBL11453570 | 0.81 | TTR (0.58) | ALDH1A1CYP3A4TDP1TP53ALOX15 | |
| SCHEMBL15340938 | 0.80 | TSHR (0.54) | ALDH1A1CYP3A4TDP1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL11452347 | 0.79 | TTR (0.56) | ALDH1A1CYP3A4TDP1TP53ALOX15 | |
| SCHEMBL22114126 | 0.78 | TTR (0.50) | ALDH1A1L3MBTL1ACHEMAPTHPGD | |
| SCHEMBL22114310 | 0.77 | L3MBTL1 (0.58) | ALDH1A1CYP3A4SMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL19843836 | 0.76 | TTR (0.61) | ALDH1A1L3MBTL1GAAACHEMAPT | |
| SCHEMBL10751638 | 0.75 | HPGD (0.54) | ALDH1A1CYP3A4SMN1; SMN2L3MBTL1GAA | |
| SCHEMBL11420788 | 0.75 | HTR2A (0.50) | ALDH1A1L3MBTL1ACHEMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695129-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL INC (US) | 2016-09-01 | — | — | US | disclosed |
| US-9000187-B2 | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | MERIAL, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251317-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | ALDH1A1 411/4885CYP3A4 25/4885TDP1 4634/4885 |
| US-20130281392-A1 | PARASITICIDAL COMPOSITIONS COMPRISING BENZIMIDAZOLE DERIVATIVES, METHODS AND USES THEREOF | LIPC, CYP3A43, CYP51A1 | ALDH1A1 411/4885CYP3A4 25/4885TDP1 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.